Medicare is expensive because it covers a large, aging population that uses more healthcare services than any other group, while the prices it pays for drugs, hospital stays, and physician services continue to climb. In 2024, the program spent $1.118 trillion, making up roughly 21% of all U.S. healthcare spending. That number is driven by a handful of reinforcing factors: more people enrolling every year, rising drug prices, a benefit structure with built-in cost escalators, and a growing share of enrollees in plans that cost the government more per person than traditional Medicare.
More People Turning 65 Every Day
The single biggest reason Medicare keeps getting more expensive is demographic. About 62 million people were enrolled in 2020. By 2030, that number is projected to reach 78 million as the entire baby-boom generation becomes eligible. That’s roughly 10,000 new beneficiaries per day during the peak enrollment years. After 2030, growth will slow, but the program will still be serving a much larger population than it was designed for.
Older adults use significantly more healthcare than younger people. They’re more likely to have multiple chronic conditions, need hospitalizations, and take several prescription drugs simultaneously. So it’s not just that more people are joining the program. Each person who joins tends to need more care than the average American, and they need it for longer as life expectancy increases.
Drug Prices That Keep Climbing
Prescription drug costs under Medicare Part D have been one of the fastest-growing pieces of the budget. Medicare’s spending on reinsurance payments for enrollees with high drug costs grew more than 20% per year on average since 2010. Three forces are behind that acceleration.
First, brand-name drug prices have risen aggressively. Manufacturers both raise prices on existing drugs and launch new specialty medications at high starting prices. The savings from generic drugs haven’t been enough to offset those increases. Second, the structure of Part D’s benefit itself creates a ratchet effect. Manufacturers are required to give a 50% discount on brand-name drugs when enrollees hit a coverage gap, but that discount counts toward the enrollee’s out-of-pocket spending limit. The result: people reach the catastrophic coverage threshold faster, shifting more of the cost to Medicare.
Third, the way plans are reimbursed in the catastrophic phase creates a perverse incentive. Plan sponsors pay only 15% of costs once an enrollee passes the out-of-pocket threshold, with Medicare picking up the rest. That makes it financially rational for a plan to put a more expensive brand-name drug on its formulary instead of a cheaper alternative, because the plan’s own share of spending actually drops while Medicare’s share balloons. The plan can use those savings to lower premiums or boost profits, but the cost to taxpayers goes up.
Medicare Advantage Costs More Per Person
More than half of Medicare beneficiaries now choose Medicare Advantage, the privately run alternative to traditional Medicare. These plans often offer extra benefits like dental and vision coverage, which makes them appealing. But they cost the federal government significantly more per enrollee.
Research from USC’s Schaeffer Center found that Medicare Advantage costs taxpayers 22% more per enrollee than traditional Medicare, adding up to roughly $83 billion a year in extra spending. Part of the problem is that the payment benchmarks the government uses to pay these private plans are set about 8% above average traditional Medicare spending before even accounting for risk adjustment. Risk adjustment is supposed to calibrate payments based on how sick a plan’s members are, but in practice it tends to inflate payments further, widening the gap between what Medicare Advantage costs and what those same enrollees would have cost in traditional Medicare.
What You Pay Out of Pocket
If you’re asking why Medicare feels expensive to you personally, the premiums and deductibles tell part of the story. The standard Part B premium for 2025 is $185 per month, up from $174.70 in 2024. The Part B annual deductible rose to $257. These increases reflect the rising cost of outpatient services, doctor visits, and medications that Part B covers.
Higher earners pay substantially more through income-related monthly adjustment amounts, known as IRMAA. For 2026, a single filer earning between $109,000 and $137,000 will pay $284.10 per month for Part B instead of the standard amount. At the top bracket, individuals earning $500,000 or more pay $689.90 per month. Married couples filing jointly hit the first surcharge at $218,000 in combined income. These surcharges also apply to Part D prescription drug coverage, adding anywhere from $14.50 to $91.00 per month on top of the plan’s base premium.
On top of premiums, most beneficiaries pay coinsurance, copays, and supplemental (Medigap) premiums that can add hundreds of dollars a month. Medicare doesn’t have an out-of-pocket maximum the way most employer plans do, so a serious illness or long hospital stay can generate large bills even with coverage in place.
Administrative Costs Are Low, but That Doesn’t Fix the Problem
One thing that’s not driving Medicare’s expense is overhead. Medicare spends about 2% of its operating budget on administration. Private insurers, by comparison, spend an estimated 17% of revenue on administrative costs. Medicare’s scale and simpler structure (no marketing, no profit margin, no underwriting) keep that number low. The problem isn’t inefficiency in running the program. It’s the sheer volume of expensive healthcare the program pays for.
The Trust Fund Is Running Out of Time
All of these cost pressures are converging on a deadline. The Medicare Hospital Insurance trust fund, which pays for Part A (inpatient hospital care), is projected to become insolvent in 2033. That doesn’t mean Medicare disappears, but it means the program would only be able to pay 89% of its costs, forcing an abrupt 11% cut to hospital payments. Hospitals that already operate on thin margins could face real financial strain, and the downstream effects on access to care could be significant.
The trust fund’s approaching shortfall is a direct consequence of the same forces pushing costs up: more beneficiaries drawing benefits, fewer workers per beneficiary paying into the system through payroll taxes, and healthcare prices that consistently outpace inflation. Without changes to revenue, benefits, or both, the math doesn’t balance. Whether that comes through higher taxes, lower payments to providers, changes to eligibility, or some combination is a political question that Congress has so far deferred.